Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Adoptive therapy for cancer using tumor-infiltrating lymphocytes (TIL) has mainly been investigated in cancer patients with advanced stage disease. The limited clinical success has not been encouraging, although this might be explained by poor TIL specificity and/or high tumor burden. To re-evaluate the effectiveness of adoptive therapy, we analyzed the capacity of tumor-reactive TIL injection in preventing the further development of disease in stage III melanoma patients after complete tumor resection. A phase II/III randomized trial was performed on 88 melanoma patients, who received autologous TIL plus interleukin-2 (IL-2) or IL-2 only. The duration of relapse-free survival was analyzed, taking into account the immunological specificity of injected TIL and the number of metastatic lymph nodes removed before treatment. Kaplan-Meyer analysis revealed that the injection of tumor-reactive TIL was statistically correlated with prolonged relapse-free survival in patients with only one metastatic lymph node. Therefore, improved clinical outcome could be obtained after adoptive therapy by selecting appropriate groups of patients and monitoring the specificity of the injected TIL populations.
Labarrière
Nathalie
N
Unité INSERM U463, 9 Quai Moncousu, 44093 Nantes Cedex 1, France.
Pandolfino
Marie-Christine
MC
Gervois
Nadine
N
Khammari
Amir
A
Tessier
Marie-Hélène
MH
Dréno
Brigitte
B
Jotereau
Francine
F
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D016219:Immunotherapy, Adoptive; D007267:Injections; D007376:Interleukin-2 / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008545:Melanoma / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D007376:Interleukin-2